NAM
BHVN

Nexpoint Asset Management’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Nexpoint Asset Management’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-237,616
Closed -$35.9M – 187
2022
Q3 		$35.9M Buy
237,616
+65,091
+38% +$9.65M 2.4% 14
2022
Q2 		$25.1M Buy
+172,525
New +$22M 2.24% 14
2020
Q4 		– Sell
-6,000
Closed -$390K – 203
2020
Q3 		$390K Hold
6,000
– – 0.09% 119
2020
Q2 		$439K Sell
6,000
-2,000
-25% -$106K 0.1% 126
2020
Q1 		$272K Sell
8,000
-16,000
-67% -$732K 0.05% 173
2019
Q4 		$1.31M Sell
24,000
-3,500
-13% -$173K 0.1% 123
2019
Q3 		$1.15M Buy
+27,500
New +$1.16M 0.07% 188

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

Nexpoint Asset Management's BHVN Position: Q4 2022 in Review

Nexpoint Asset Management sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 237,616 shares — an estimated $35.9M sold.

Nexpoint Asset Management first reported a position in BHVN in Q3 2019 and held it in 7 quarters. The position peaked at $35.9M in Q3 2022. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • Nexpoint Asset Management reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • Nexpoint Asset Management sold 237,616 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $35.9M.
  • Nexpoint Asset Management first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q3 2019 and held it in 7 quarters.
  • Nexpoint Asset Management's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $35.9M in Q3 2022.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on Nexpoint Asset Management's 13F filing for Q4 2022, filed 14 Feb 2023.